In combination with PD-L1 or CTLA-4 targeted therapy, anti-VISTA antibody therapy has shown tumour regression and synergistic effect in preclinical tumour models, suggesting it might help overcome immune check point inhibitor drug resistance [16–18]. This evidence concerns the gene CD274 and neoplasm.